Zynerba Pharmaceuticals, Inc.

NasdaqCM:ZYNE Stock Report

Market Cap: US$65.6m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Zynerba Pharmaceuticals Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Armando Anido

Chief executive officer

US$1.9m

Total compensation

CEO salary percentage33.65%
CEO tenure9yrs
CEO ownership1.9%
Management average tenure6.8yrs
Board average tenure8.2yrs

Recent management updates

Recent updates

Analysis Article • Mar 01

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Nov 11

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Oct 06

Zynerba stock rises on US patent for cannabidiol Zygel's use for Fragile X syndrome

Zynerba Pharmaceuticals (NASDAQ:ZYNE) said the U.S. Patent and Trademark Office issued a patent covering methods of treating Fragile X syndrome (FXS) with cannabidiol. The patent no. 11,458,110, titled 'Treatment of Fragile X Syndrome With Cannabidiol' will expire in 2038, is part of the Zynerba's intellectual property portfolio covering its transdermal cannabidiol product candidate Zygel, the company said in an Oct. 6 press release. FXS a genetic disorder due to changes in a gene called Fragile X Messenger Ribonucleoprotein 1 (FMR1) and causes developmental delays, learning disabilities and behavior problems, according to the U.S. CDC. ZYNE +4.99% to $0.77 premarket Oct. 6
Seeking Alpha • Aug 10

Zynerba Pharmaceuticals GAAP EPS of -$0.24 misses by $0.01

Zynerba Pharmaceuticals press release (NASDAQ:ZYNE): Q2 GAAP EPS of -$0.24 misses by $0.01. As of June 30, 2022, cash and cash equivalents were $62.5 million, compared to $67.8 million as of December 31, 2021. Management believes that the Company’s cash and cash equivalents are sufficient to fund operations and capital requirements through the end of 2023 or into early 2024, after the expected availability of topline results from its confirmatory pivotal Phase 3 RECONNECT trial of Zygel in patients with FXS.
Analysis Article • Jul 22

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Jul 21

Zynerba inks equity funding contract of up to $20M with Lincoln Park Capital

Zynerba Pharmaceuticals (NASDAQ:ZYNE) signed an equity purchase agreement for up to $20M with Chicago-based Lincoln Park Capital Fund. Under the agreement, the cannabinoid therapy maker will have the right, to sell up to $20M worth of common shares to LPC over the three year term of the contract. Zynerba said any stock sold will be at  market prices prevailing at that time. The company expects to use any net proceeds from the sale for working capital and general corporate purposes, including research and development expenses and capital expenditures. Zynerba noted that it may terminate the agreement at any time without any cost or penalty.
Analysis Article • Mar 23

Here's Why We're Watching Zynerba Pharmaceuticals' (NASDAQ:ZYNE) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Dec 02

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • May 27

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Nov 23

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although...

CEO Compensation Analysis

How has Armando Anido's remuneration changed compared to Zynerba Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2023n/an/a

-US$38m

Mar 31 2023n/an/a

-US$37m

Dec 31 2022US$2mUS$633k

-US$35m

Sep 30 2022n/an/a

-US$36m

Jun 30 2022n/an/a

-US$38m

Mar 31 2022n/an/a

-US$38m

Dec 31 2021US$2mUS$603k

-US$37m

Sep 30 2021n/an/a

-US$38m

Jun 30 2021n/an/a

-US$37m

Mar 31 2021n/an/a

-US$47m

Dec 31 2020US$1mUS$585k

-US$51m

Sep 30 2020n/an/a

-US$52m

Jun 30 2020n/an/a

-US$45m

Mar 31 2020n/an/a

-US$36m

Dec 31 2019US$1mUS$568k

-US$33m

Sep 30 2019n/an/a

-US$30m

Jun 30 2019n/an/a

-US$36m

Mar 31 2019n/an/a

-US$37m

Dec 31 2018US$2mUS$568k

-US$40m

Sep 30 2018n/an/a

-US$40m

Jun 30 2018n/an/a

-US$41m

Mar 31 2018n/an/a

-US$37m

Dec 31 2017US$2mUS$552k

-US$32m

Sep 30 2017n/an/a

-US$31m

Jun 30 2017n/an/a

-US$28m

Mar 31 2017n/an/a

-US$26m

Dec 31 2016US$901kUS$536k

-US$23m

Compensation vs Market: Armando's total compensation ($USD1.88M) is above average for companies of similar size in the US market ($USD649.07K).

Compensation vs Earnings: Armando's compensation has been consistent with company performance over the past year.

CEO

Armando Anido (65 yo)

9yrs
Tenure
US$1,881,402
Compensation

Mr. Armando Anido, MBA, has been the Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, Inc. since October 2014. Mr. Anido has been an Independent Director of SCYNEXIS, Inc. since January 21,...

Leadership Team

NamePositionTenureCompensationOwnership
Armando Anido
Chairman & CEO9yrsUS$1.88m1.94%
$ 1.3m
Terri Sebree
President9yrsUS$1.38m1.18%
$ 775.1k
James Fickenscher
CFO & VP of Corporate Development (Leave of Absence)7.1yrsUS$1.26m0.75%
$ 491.5k
Kenneth Jones
VP, Corporate Controller & Interim CFO6.6yrsno data0.17%
$ 111.2k
Albert Parker
Chief Legal Officer & Corporate Secretary1.7yrsno data0.45%
$ 295.1k
Joseph Apostolico
Vice President of Human Resources5.6yrsno datano data
6.8yrs
Average Tenure
59yo
Average Age

Experienced Management: ZYNE's management team is seasoned and experienced (6.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Armando Anido
Chairman & CEO9yrsUS$1.88m1.94%
$ 1.3m
Kenneth Moch
Independent Director8.2yrsUS$107.50k0.15%
$ 98.5k
Daniel Kisner
Independent Director8.2yrsUS$105.00k0.15%
$ 98.5k
Warren Cooper
Lead Independent Director8.2yrsUS$135.00k0.15%
$ 98.5k
John Butler
Independent Director5.5yrsUS$102.50k0.16%
$ 105.0k
William Federici
Independent Director8.2yrsUS$110.00k0.15%
$ 98.5k
Steven Siegel
Member of Scientific Advisory Boardno datano datano data
Randi Hagerman
Member of Scientific Advisory Board8yrsno datano data
Elizabeth Berry-Kravis
Member of Scientific Advisory Boardno datano datano data
Nicole Tartaglia
Member of Scientific Advisory Board7yrsno datano data
Pamela Stephenson
Independent Director4.7yrsUS$100.00k0.15%
$ 98.5k
Craig Erikson
Member of Scientific Advisory Boardno datano datano data
8.2yrs
Average Tenure
65yo
Average Age

Experienced Board: ZYNE's board of directors are considered experienced (8.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/10/12 16:14
End of Day Share Price 2023/10/10 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Zynerba Pharmaceuticals, Inc. is covered by 13 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Corey DavisCanaccord Genuity
Elemer PirosCantor Fitzgerald & Co.
Oren LivnatH.C. Wainwright & Co.